<p><strong>Patients with HIV and Hepatitis B virus Coinfection</strong>: Safety and efficacy of Lamivudine have not been established for treatment of chronic hepatitis B in patients dually infected with HIV and HBV. Emergence of hepatitis B virus variants associated with resistance to Lamivudine has also been reported in HIV-infected patients who have received Lamivuuine-containing antiretroviral regimens in the presence of concurrent infection with Hepatitis B virus. Post-treatment exacerbations of hepatitis have also been reported.<br />
<br />
<strong>Patients with Impaired Renal Function</strong>: Reduction of the dosages of Lamivudine and Zidovudine is recommended for patients with impaired renal function. Patients with creatinine clearance &lt;50 ml/min should not receive this combination tablet.<br />
<br />
<strong>Fat Redistribution</strong>: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast<br />
enlargement, and cushingoid appearance have been observed in patients receiving antiretroviral therapy.</p>